- Diaveridine
-
- $33.00 / 500mg
-
2025-09-30
- CAS:5355-16-8
- Min. Order:
- Purity: 99.19%
- Supply Ability: 10g
- Diaveridine
-
- $0.00 / 25KG
-
2025-08-08
- CAS:5355-16-8
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 50000KG/month
- Diaveridine
-
- $6.00 / 1kg
-
2025-07-29
- CAS:5355-16-8
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 2000KG/Month
|
| | Diaveridine Basic information |
| Product Name: | Diaveridine | | Synonyms: | DIAVERIDIN;DIAVERIDINE;5-[(3,4-DIMETHOXYPHENYL)METHYL]-2,4-PYRIMIDINEDIAMINE;5-(3,4-DIMETHOXYBENZYL)-2,4-PYRIMIDINEDIAMINE;5-(3,4-DIMETHOXY-BENZYL)-PYRIMIDINE-2,4-DIAMINE;2,4-DIAMINO-5-(3,4-DIMETHOXY BENZYL)PYRIMIDINE;2,4-Diamino-5-veratrylpyrimidine;5-(3,4-Dimethoxybenzyl)-2,4-diaminopyrimidine | | CAS: | 5355-16-8 | | MF: | C13H16N4O2 | | MW: | 260.29 | | EINECS: | 226-333-3 | | Product Categories: | | | Mol File: | 5355-16-8.mol |  |
| | Diaveridine Chemical Properties |
| Melting point | 233° | | Boiling point | 506.1±60.0 °C(Predicted) | | density | 1.252±0.06 g/cm3(Predicted) | | storage temp. | Keep in dark place,Inert atmosphere,2-8°C | | solubility | DMSO (Slightly) | | pka | 7.11±0.10(Predicted) | | form | Solid | | color | White to Pale Yellow | | Merck | 13,3017 | | BRN | 258464 | | InChI | InChI=1S/C13H16N4O2/c1-18-10-4-3-8(6-11(10)19-2)5-9-7-16-13(15)17-12(9)14/h3-4,6-7H,5H2,1-2H3,(H4,14,15,16,17) | | InChIKey | LDBTVAXGKYIFHO-UHFFFAOYSA-N | | SMILES | C1(N)=NC=C(CC2=CC=C(OC)C(OC)=C2)C(N)=N1 | | CAS DataBase Reference | 5355-16-8(CAS DataBase Reference) |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | WGK Germany | 2 | | RTECS | UV8142000 | | HS Code | 29335990 |
| | Diaveridine Usage And Synthesis |
| Uses | Antibacterial. | | Uses | Diaveridine is a dihydrofolate reductase inhibitor. It is used in veterinary medicine as a drug for its anticoccidial properties and its function as an antibacterial synergist. | | Definition | ChEBI: An aminopyrimidine in which the pyrimidine ring carries amino substituents at C-2 and C-4 and a 3,4-dimethoxybenzyl group at C-5. A folic acid antagonist, it is used as a synergist with sulfonamides against the parasitic Eimeria species. | | in vivo | The sperm abnormality of the Diaveridine (DVD) treatment groups at all dose levels (Diaveridine, 128 to 512 mg/kg) shows no significant differences compare with the negative control group. There are no significant differences of micronucleus between the negative control group and the Diaveridine treatment groups (Diaveridine, 128 to 512 mg/kg). The chromosome aberration of the Diaveridine treatment groups at all dose levels and the negative control group are significantly lower than those in the positive control group treated with cyclophosphamide (P<0.05), indicating that Diaveridine at the doses studied does not cause abnormal chromosome aberration. The results demonstrate that the Diaveridine administration does not produce significant changes in the ratio of organ-to-body weight, compare with the negative control group in the end period of the study[3]. |
| | Diaveridine Preparation Products And Raw materials |
|